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RP105, phylogenetically related to Toll-like receptor
(TLR)-4, is reported to facilitate B cell activation by
the TLR4-agonist lipopolysaccharide (LPS)—but to
limit LPS-induced cytokine production by antigen-
presenting cells. Here, we show that the role of
RP105 extends beyond LPS recognition and that
RP105 positively regulates macrophage responses
to Mycobacterium tuberculosis (Mtb) lipoproteins.
Mtb-infected RP105/ mice exhibited impaired
proinflammatory cytokine responses associated
with enhanced bacterial burden and increased lung
pathology. The Mtb 19 kDa lipoprotein induced
release of tumor necrosis factor in a manner depen-
dent on both TLR2 and RP105, and macrophage acti-
vation by Mtb lacking mature lipoproteins was not
RP105 dependent. Thus, mycobacterial lipoproteins
are RP105 agonists. RP105 physically interacted
with TLR2, and both RP105 and TLR2 were required
for optimal macrophage activation by Mtb. Our data
identify RP105 as an accessory molecule for TLR2,
forming part of the receptor complex for innate
immune recognition of mycobacterial lipoproteins.
INTRODUCTION
Toll-like receptors (TLRs) recognize conserved motifs of micro-
bial molecules and initiate signal transduction leading to the
induction of innate and acquired immune responses (Medzhitov
and Janeway, 2000; Takeda et al., 2003). Agonists have been
identified for most members of the TLR family, and the signaling
events that result from TLR activation have been extensively
studied (Kawai and Akira, 2005). However, such studies only
incompletely mimic the interaction of host cells with pathogens,
which are complex immunogens with various biochemical
components that may engage several receptors at once. Inter-
actions between members of the TLR family have been demon-
strated. TLR2, for example, forms heterodimers either with TLR1
or with TLR6 to discriminate between di- or triacylated lipopep-Celtides (Takeda et al., 2003). Engagement of different intracellular
adaptors results in a certain degree of signal specificity down-
stream of TLRs (Kawai and Akira, 2005). Furthermore, TLRs
can work in conjunction with accessory proteins. For example,
CD36 facilitates recognition of diacylated lipoproteins by the
TLR2/6 complex (Hoebe et al., 2005).
Mycobacterium tuberculosis (Mtb) engages a multitude of
surface receptors on macrophages, leading to uptake (Ernst,
1998), cell activation and establishment of an adaptive immune
response (Flynn and Chan, 2005). TLR2, TLR9, and TLR4 are
involved in host cell activation by mycobacteria and their prod-
ucts (Bafica et al., 2005; Means et al., 1999; Underhill et al.,
1999), yet results addressing the importance of individual TLRs
in host resistance in in vivo models of tuberculosis are conflicting
(Doherty and Arditi, 2004; Bafica et al., 2005; Holscher et al.,
2008). Cooperative activation of receptors may shape the host
immune response to Mtb, as suggested by the observation
that TLR2 and TLR9 act synergistically to mediate resistance
to Mtb infection (Bafica et al., 2005).
RP105 (radioprotective 105 kDa) is a TLR-like protein that is
expressed by B lymphocytes, macrophages, and dendritic cells
(DCs) (Blumenthal et al., 2005; Divanovic et al., 2005; Fugier-
Vivier et al., 1997; Miura et al., 1996; Miyake et al., 1995). Phylo-
genetic analyses placed RP105 and TLR4 into the same
subfamily (Divanovic et al., 2005). Similar to TLR4, which is asso-
ciated with the extracellular protein MD-2, surface expression of
RP105 depends on its association with the soluble MD-2
homolog, MD-1 (Miyake et al., 1998; Nagai et al., 2002). RP105
contains the conserved extracellular leucine-rich repeat domain
typical for members of the TLR family (Miyake et al., 1995) but
lacks the intracellular Toll/IL-1-receptor- (TIR-) domain, which
is essential for TLR signaling. Instead, RP105 contains only
6–11 intracytoplasmic amino acid residues and may associate
with other signaling molecules to mediate intracellular signal
transduction (Kimoto et al., 2003).
The role of RP105/MD-1 in cellular activation has been studied
with focus on the TLR4 agonist lipopolysaccharide (LPS) as the
stimulating agent. The ex vivo proliferation of B cells from
RP105-deficient (/) and MD-1/mice was blunted compared
to wild-type (WT) cells; in vivo, a reduction in LPS-driven anti-
body production has been reported (Nagai et al., 2002; Ogata
et al., 2000). In contrast, in macrophages and DCs, RP105 wasl Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc. 35
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RP105 Is a Coreceptor for TLR2shown to inhibit LPS-induced TLR4-mediated activation as
demonstrated by elevated levels of inflammatory cytokines in
cultures of LPS-stimulated RP105/ cells. Similarly, injection
of RP105/mice with LPS led to increased TNF (tumor necrosis
factor) concentration in serum, alongwith increased endotoxicity
(Divanovic et al., 2005). Studies with transfected HEK293 cells
revealed that the RP105/MD-1 complex interacts directly with
TLR4/MD-2 and inhibits LPS binding without binding LPS
directly (Divanovic et al., 2005; Tsuneyoshi et al., 2005).
Little is known about RP105 involvement in TLR4-independent
activation of host cells. Responses to synthetic TLR2 agonists,
such as the lipopeptides Pam3CSK4 and MALP-2, have been
reported to be impaired in RP105/ B cells; however, in
RP105/ macrophages and DCs, TNF production in response
to these TLR2 agonists was not different from that in WT cells
(Nagai et al., 2005). Cell-specific differences seem to determine
the different roles for RP105 in mediating cell activation. This
hypothesis is supported by the finding that in B cells crosslinking
of RP105 by a specific antibody-induced proliferation (Miyake
et al., 1994), whereas the same antibody failed to activate
macrophages or DCs (Divanovic et al., 2005; Kimoto et al., 2003).
Informationabout the roleofRP105during infectiousprocesses
in vivo is limited. RP105/ mice were used to investigate LPS-
induced systemic inflammation. These studies indicated that
RP105 is involved in dampening inflammatory responses during
LPS-induced sepsis (Divanovic et al., 2005; Nagai et al., 2005).
RP105/micewere also reported to control infectionwith Leish-
mania major better than WT mice (Divanovic et al., 2007).
Wedemonstrate that infection of primarymousemacrophages
withMtb led to increasedsurfaceexpressionofRP105andMD-1.
RP105 and MD-1 were required for optimal release of IL-12p40,
TNF, IL-10, and RANTES by macrophages following Mtb infec-
tion. We provide evidence that RP105 enhances TLR2 signaling
in Mtb-infected macrophages: (1) the Mtb 19 kDa lipoprotein,
a TLR2 agonist, stimulated macrophages in an RP105-depen-
dent fashion; (2) RP105/MD-1 enhanced TLR2-dependent
IL-12p40 and TNF production by Mtb-infected macrophages;
and (3) RP105 copatched with aggregated TLR2 in the plasma
membrane, and both receptors coimmunoprecipitated, indi-
cating physical interactions between TLR2 and RP105. Further-
more, RP105 was found to be important for early cytokine
responsesduringanMtb infection, andmodulatedmycobacterial
replication and pathology in lungs of chronically infected mice.
RESULTS
Microbial Stimulation Increases RP105 and MD-1
Surface Expression by Macrophages
Flow cytometry was used to measure cell surface expression of
RP105 by murine bone marrow-derived macrophages (BMM)
after stimulation with viable Mtb. While at 4 hr after stimulation
RP105 surface expression was unaltered (data not shown),
a dose-dependent increase in RP105 expression, compared to
unstimulated cells, was detected 18 hr after exposure to Mtb
(Figures 1A and 1C). The elevated RP105 surface expression
was preceded by an increase in mRNA expression (Figure 1E)
and did not require TLR2 (Figure S1A).
MD-1 is associated with RP105 and is essential for RP105
surface expression (Miyake et al., 1998; Nagai et al., 2002). We36 Cell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elseviertherefore also analyzed expression of MD-1 by macrophages.
Surface expression of MD-1 was enhanced after Mtb stimulation
(Figures 1B and 1D) similar to that of RP105. However, MD-1
mRNA levelswerenotdifferent fromunstimulatedcells (Figure1F),
suggesting a posttranscriptional mechanism for increased MD-1
surface expression—e.g., redistribution from an intracellular
pool. Mtb-induced upregulation of MD-1 occurred independently
of TLR2 (Figure S1A). In RP105/ BMM lower amounts of MD-1
weredetectedon the surface than inWTcells (FigureS1B), but the
fold increase in MD-1 surface expression upon Mtb stimulation
was similar to WT cells (Figure S1A).
RP105 Is Required for Optimal Activation
of Macrophages by Mtb and Contributes to Host
Resistance against Mtb Infection
To test if RP105 is involved in Mtb-induced macrophage activa-
tion, we examined responses of WT and RP105/ BMM to
Mtb. Uptake and intracellular survival of Mtb were similar in
both genotypes (Figure S2). Infection of WT BMM with live Mtb
induced expression of genes encoding inflammatory cytokines
(TNF, IL-6, IL-10, IL-12p40, and IFNb), chemokines (IP-10,
RANTES,MCP-1, KC [mouse homolog of GRO-a]), and inducible
nitric oxide synthase (iNOS) (Figures 2A and S3). In Mtb-infected
RP105/macrophages, IL-12p40mRNA levels were decreased
by60%–70%compared to those inWTmacrophages (Figure2A).
In contrast, nine other genes showed similar mRNA levels in WT
andRP105/BMMfollowingMtb challenge (Figures 2A andS3).
IL-12p40 protein levels were reduced by 50% in RP105/
BMMcompared toWTBMM(Figure 2B), consistentwith reduced
IL-12p40mRNA levels in thesecells.Moreover, although similarly
expressed at the mRNA level, TNF, IL-10, and RANTES pro-
tein amounts were reduced in supernatants of Mtb-infected
RP105/ BMM (Figure 2B). These data show that RP105
contributed to transcriptional and posttranscriptional regulation
of Mtb-induced expression of inflammatory genes.
In contrast toMtb-induced activation, stimulation of RP105/
macrophages with LPS, or the TLR2 agonist Pam3CSK4, and
peptidoglycan did not lead to reduced levels of TNF, IL-12p40,
IL-10, or RANTES (Figure 3A).
To assess the role of RP105 in resistance and inflammatory
responses to Mtb infection in vivo, we analyzed systemic IL-
12p40 concentrations, bacterial loads, and pulmonary pathology
in RP105/ and WT mice infected with a low dose of virulent
Mtb via the aerosol route. RP105/ mice had 50% lower
IL-12p40 serum levels during the acute phase of infection at
days 7 and 21 (Figure 2C). With the decline of serum-IL-12p40
in WT mice at later time points, these differences subsided.
IL-12p40 in RP105/ mice did not accumulate to the levels
observed inWT animals at 3weeks postinfection. Bacterial loads
in lungs of RP105/mice were similar at day 7 post infection but
elevated compared toWTmice at 21, 56, and 85 days post infec-
tion with significant differences at days 56 and 85 (Figure 2D).
This was observed in two independent experiments. Survival
of RP105/ mice was not compromised within the duration of
the experiment (85 days).
RP105/ and WT mice showed an effective granulomatous
response in lung tissue (Figure 2F), and themononuclear infiltrate
(macrophages, foamy macrophages, lymphocytes, isolated
polymorphonuclear cells) was similar. However, at days 21 andInc.
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RP105 Is a Coreceptor for TLR256 RP105/ mice had more numerous and larger inflammatory
lesions in their lungs thanWTmice (Figures 2E and2F). Especially
at day 56, in the chronic phase of infection, the ratio between
macrophage infiltrated areas and lymphocyte foci in the same
lesion was higher in RP105/ mice than in WT controls and
lesions in RP105/ mice appeared less organized than in WT
animals (Figure 2F). A similar trend of exacerbated pathology
and elevated bacterial burden in the chronic phase of infection
in lungs of RP105/ mice was seen after infection with a high
dose of Mtb (Figure S4). However, accumulation of IL-12p40 in
serum followed a different kinetic than after low dose infection
and IL-12p40 levels were not found to be significantly different
during the acute phase (Figure S4). Such loss of early differences
in immune responses dependent on the infectious dose has
been reported previously in a Leishmania major infection model
Figure 1. Mtb-Induced Upregulation of RP105 and MD-1 Expression
by Macrophages
(A–D) Expression of RP105 (A) and MD-1 (B) by BMM, unstimulated (unst.) or
infected withMtb (MOI 10; 18 hr). Data are from one experiment representative
of three. Mtb-induced increase in surface expression of RP105 (C) and MD-1
(D) by macrophages is dose dependent. Median fluorescence intensities (MFI)
for isotype control stainings were subtracted from MFI for specific antibody
stainings. One representative experiment of two is depicted.
(E and F) RP105 (E) and MD-1 (F) mRNA levels normalized to GAPDH from
Mtb-stimulated and unstimulated BMM at indicated times. Data represent
means of triplicates ± SD. Results from one experiment out of two are shown.Cel(Divanovic et al., 2007) and suggests that the detection of
RP105-dependent immune responses might be obscured under
conditions of high initial pathogen burden.
Mtb Lipoproteins Activate Macrophages
in an RP105-Dependent Manner
In the cell wall of Mtb, peptidoglycan is covalently linked to
arabinogalactan, which at its distal ends is esterified with my-
colic acids (mycolyl-arabino-galactan peptidoglycan [mAGP]).
Lipoproteins are located in the cell wall, and the outer layer
of the mycobacterial cell envelope contains free glycolipids
and lipids, which can be extracted with chloroform-methanol
(Brennan and Nikaido, 1995; Young and Garbe, 1991). To iden-
tify which subcellular structure of Mtb confers RP105-dependent
macrophage activation, BMMwere stimulated with four different
isolated mycobacterial cell envelope components: (1) purified
mAGP, (2) a chloroform-methanol extracted lipid fraction of
whole cells, (3) purified phosphatidyl inositol mannosides
(PIM), and (4) purified 19 kDa lipoprotein, an extensively studied
immunomodulatory antigen of Mtb. There were no significant
differences in TNF release between WT and RP105/ macro-
phages after stimulation with mAGP, the lipid extract, and the
PIM preparation (Figure S5), suggesting that these cell wall
constituents activate macrophages independently of RP105.
TNF responses in TLR2/ macrophages were abolished in
response to total lipid and PIM preparations, while mAGP-
induced TNF production was largely independent of TLR2,
consistent with previous data (Fortune et al., 2004).
Mycobacterial lipoproteins have been implicated in activating
innate immune responses, and it has been shown that the 19 kDa
lipoprotein of Mtb is a potent TLR2 agonist (Brightbill et al., 1999;
Thoma-Uszynski et al., 2001). Stimulation with the Mtb 19 kDa
lipoprotein and a synthetic tripalmitoylated hexadecapeptide,
which contains the N-terminal amino acid sequence of the
19 kDa lipoprotein, resulted in significantly reduced TNF levels
in both RP105/ and TLR2/ macrophages compared to WT
macrophages (Figures 3B and 3C). Thus, the 19 kDa lipoprotein
induced TNF production in an RP105- and TLR2-dependent
manner. Of note, phosphorylation of p38, JNK, and IkB-a,
signaling events involved in TNF gene and protein expression,
was unimpaired in RP105/ BMM after stimulation with the
19 kDa lipoprotein and the synthetic lipopeptide, similar to stim-
ulation with Pam3CSK4 (Figure 3E). In splenic B cells from
RP105/ mice, upregulation of CD69 and CD86, surface
proteins indicative of cellular activation, was reduced compared
to WT B cells after stimulation with the synthetic lipopeptide
(Figure S6). Taken together, these data identified the 19 kDa lipo-
protein of Mtb as an RP105 agonist and raised the question if
other RP105 agonists were present in Mtb.
An Mtb mutant lacking the 19 kDa lipoprotein (Stewart et al.,
2005) was not different from wild-type Mtb in that it required
RP105 for full induction of TNF release from BMM (data not
shown). This suggested that Mtb expresses other RP105
agonists, which might also be lipoproteins. To test this hypoth-
esis, an Mtb strain with a mutated copy of the lspA gene (DlspA),
which encodes a lipoprotein signal peptidase, was used. Inacti-
vation of LspA in Mtb has been demonstrated to interrupt matu-
ration of lipoproteins, including the 19 kDa lipoprotein, at the
stage of signal peptide cleavage (Banaiee et al., 2006; Sanderl Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc. 37
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RP105 Is a Coreceptor for TLR2Figure 2. RP105 Is Required for Optimal Macrophage Activation in Response to Mtb Infection and Participates in Control of Mtb Infection
In Vivo
(A) mRNA levels in BMMstimulated withMtb (MOI 3, 4 hr) or unstimulated. Data representmeans of triplicates ± SD. Comparison of raw data of three independent
wells by unpaired t test showed a significant difference in IL-12p40 mRNA expression (*P =0 .0032), but no differences for TNF, IL-10, and RANTES. One repre-
sentative experiment out of two is shown.
(B) Cytokine and chemokine release by Mtb-stimulated WT and RP105/macrophages (MOI 1 or 3, 24 hr). Data represent means ± SD of three parallel cultures
in a single experiment and are representative of three independent experiments.
(C–F) Infection of WT and RP105/ mice with a low dose of Mtb (175 ± 98 CFU/lung).
(C) IL-12p40 concentrations in serum at indicated times post infection (p.i.). Means are indicated. Groups were compared by unpaired t test. *P < 0.05, ***P%
0.0005. Results of one experiment out of two are shown.
(D) Colony-forming units (CFU) in lungsmonitored over time.Means are indicated. Groupswere compared by unpaired t test. *P < 0.05, **P < 0.002. Results of one
experiment out of two are shown.
(E) Number of lesions per lung section on day 56. Means of the number of lesions in one lung section of five mice per group ± se are shown. Groups were
compared by unpaired t test. *P = 0.0239.
(F) Exacerbated pathology in lungs of Mtb infected RP105/mice. Tissue sections were stained with hematoxylin and eosin. Representative sections from one
mouse per genotype out of five are shown; two independent experiments were performed. (Bar = 100 mm).38 Cell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc.
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RP105 Is a Coreceptor for TLR2Figure 3. Mtb Lipoproteins Activate Macrophages in an RP105-Dependent Fashion
(A) Cytokine responses of WT and RP105/macrophages after 24 hr stimulation with Pam3CSK4 (10 ng/ml), peptidoglycan (PGN, 10 mg/ml), or LPS (10 ng/ml),
respectively. Means ± SD of triplicate wells of one representative out of three (Pam3CSK4, LPS) or two (PGN) experiments are shown. Of note, theminor enhance-
ment of cytokine production seen in RP105/ cells, might be due to a low amount of TLR2-dependent agonists in the LPS preparation; heterologous TLR stim-
ulation has been shown to overcome RP105-mediated inhibition of TLR4 stimulation (Divanovic et al., 2005).
(B) TNF concentrations in supernatants of WT, RP105/, and TLR2/ BMM after stimulation with the 19 kDa lipoprotein of Mtb or the synthetic lipopeptide
(resembling the 16 N-terminal amino acids of the 19 kDa lipoprotein) for 24 hr. Raw data of three independent wells were compared by unpaired t test. *P <
0.05, **P < 0.005, ***P < 0.0001. Data are means ± SD of triplicate wells of one experiment representative of four.
(C) TNF concentrations in culture supernatants of WT and RP105/ after stimulation with the synthetic lipopeptide (1 mg/ml). Data are means ± SD of five inde-
pendent wells of one experiment representative of two.
(D) TNF produced byWT and RP105/macrophages infected withWTMtb,DlspA, orDlspA comp. (MOI 3) wasmeasured after 24 hr. Data represent means ± se
of four independent experiments (performed in triplicates). Paired t test was used for comparison. *P = 0.0267; **P = 0.0066.
(E) Immunoblot analyses of p38-, JNK-, and IkB-a phosphorylation (P) on lysates of WT, RP105/, and TLR2/ BMM after stimulation with 19 kDa lipoprotein,
synthetic lipopeptide (both 1 mg/ml), Pam3CSK4 (10 ng/ml), or treatment with DMSO (D) for indicated times. Total amounts of p38 were detected as control for
equal loading. Data represent one out of three independent experiments.et al., 2004). However, the fatty acid and mycolic acid composi-
tion aswell as the overall architecture of theMtb cell envelope re-
mained unaltered in Mtb lacking LspA (Sander et al., 2004). WT
and RP105/ macrophages were infected with either wild-type
Mtb, the DlspA strain, or the mutant strain reconstituted with
the WT allele (DlspA comp.). Compared to wild-type Mtb, the
DlspA strain elicited marginally reduced TNF levels inWTmacro-
phages at 24 hr post stimulation, which is in agreement with
previous data (Banaiee et al., 2006). This suggests that other
structural components of Mtb can partially compensate for the
loss of mature lipoproteins in this mutant in inducing TNF. As
expected, the TNF responses to wild-type Mtb and comple-
mented lspA mutant were significantly reduced in RP105/
macrophages (Figure 3D). In contrast, infection with the DlspA
strain resulted in similar TNF levels in WT and RP105/ macro-Celphages (Figure 3D). This demonstrates that Mtb lacking mature
lipoproteins induced TNF production independently of RP105
and suggests a role forRP105 in signaling the presence ofmature
Mtb lipoproteins.
RP105 Interacts with TLR2
Because bacterial lipoproteins have been shown to activate cells
via TLR2, we investigated if RP105 could interact with TLR2. The
plasma membrane distributions of fluorescently labeled RP105
and TLR2 were visualized by confocal microscopy (Figure 4A).
Both are integral membrane proteins that showed a largely
uniform distribution pattern, and this was not detectably altered
by stimulation with heat-killed Mtb (Figure 4A and data not
shown). Fluorescent labeling and imaging of CD14 and MHCII
showed that other membrane proteins exhibited similarl Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc. 39
Cell Host & Microbe
RP105 Is a Coreceptor for TLR2Figure 4. RP105 and TLR2 Colocalize and Associate in the Cell Membrane
(A) WT BMM were incubated with heat-killed Mtb for 2 hr and stained with anti-TLR2 or mIgG1 isotype control antibodies that were specifically labeled with
Alexa488-conjugated Fab fragments. After PFA fixation, cells were incubated with anti-RP105 or anti-CD14 antibody or matched isotype control (rIgG2a)
followed by an Alexa547 conjugated anti-rat secondary antibody. Samples were analyzed by confocal microscopy (DIC = differential interference contrast in
transmitted light images; merge = overlay of images acquired in different fluorescence channels).
(B) WTmacrophages were incubated with heat killedMtb for 2 hr and stained with anti-TLR2 or IgG1 isotype control antibodies that were specifically labeled with
Alexa488-conjugated Fab fragments. Patching was achieved by crosslinking of the anti-TLR2 or mouse IgG1 antibodies with an anti-mouse antibody. After fixa-
tion cells were costained for RP105 or CD14 expression as described under (A). Data shown are representative for four (RP105) and two (CD14) independent
experiments. Enlarged overlay images are depicted on the right. White arrowheadsmark start and end points of line scans for acquisition of fluorescence profiles
depicted in panel (C).40 Cell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc.
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RP105 Is a Coreceptor for TLR2distribution patterns (Figure 4A, not shown for MHCII). To deter-
mine if TLR2 and RP105 associate, TLR2 was aggregated at the
cell surface with antibodies, and the effects on the distribution of
RP105, CD14, and MHCII were analyzed. Incubation of BMM on
ice with a specific primary antibody against TLR2, followed by
crosslinking with a secondary antibody, led to formation of
TLR2 patches in the cell membrane (Figure 4B). After fixation,
cells were costained for RP105, CD14, and MHCII. RP105, but
not CD14 or MHCII, redistributed with patched TLR2 (Figure 4B
and not shown for MHCII). Fluorescence intensity line scans
acquired over a distance of approximately 35 mm along the
periphery of cells demonstrated almost complete overlap of the
TLR2 and RP105 (but not CD14) -specific signals (Figure 4C).
These data suggest a close association between TLR2 and
RP105, rather than nonspecific coaggregation of all membrane
proteins. Copatching of RP105 and TLR2 was observed in unsti-
mulated and Mtb-stimulated macrophages (Figure 4B and data
not shown). Analyses of TLR2/ and RP105/ macrophages
showed specificity of the staining and demonstrated unaltered
expression and distribution of TLR2 and RP105 if either partner
was not expressed (Figure 4D).
We next examined if TLR2 physically interacted with RP105.
Ba/F3 cells transfected with RP105/MD-1 and TLR2 as well
as RAW264.7 macrophages were used. Flow cytometry con-
firmed surface expression of endogenous RP105 and TLR2
by RAW264.7 macrophages and successful transfection of
Ba/F3 cells (data not shown). RP105 and TLR2 bidirectionally
coimmunoprecipitated in both experimental settings (Figures
4E and 4F) indicating a physical association between both
receptors. In contrast, an isotype-matched control antibody
did not precipitate RP105 or TLR2 (Figures 4E and 4F). These
data demonstrate a physical interaction between RP105 and
TLR2 and suggest that RP105/MD-1 and TLR2 are present in
heteromeric complexes in the cell membrane of macrophages.
RP105/MD-1 Cooperates with TLR2 in Macrophage
Activation by Mtb
RP105 lacks an intracellular TIR domain and may require
a signaling-competent partner (Kimoto et al., 2003) to participate
in macrophage activation. Because RP105 interacted physically
with TLR2, we tested if RP105 cooperates with TLR2 to trigger
Mtb-induced macrophage activation. RP105/MD-1 can form
a complex with TLR4/MD-2 and negatively regulate LPS-
induced activation of macrophages and DCs (Divanovic et al.,
2005). Therefore, we also investigated if TLR4 is involved in
RP105-dependent responses to Mtb. TNF and IL-12p40 levels
were significantly reduced in supernatants from RP105/ and
TLR2/ cells (Figure 5A). TLR2 deficiency had a more extensive
impact on cytokine production than RP105 deficiency, indicating
that Mtb triggers TLR2-dependent pathways leading to cytokine
production, which are independent of RP105. Cytokine produc-Celtion by TLR2/ cells was dramatically reduced but not abol-
ished, and the additional lack of RP105 in RP105/TLR2/ cells
did not result in further decreased cytokine levels. These data
suggest that RP105 required the presence of TLR2 to contribute
to Mtb-induced macrophage activation. In contrast, TNF and
IL-12p40 levels in supernatants from Mtb-infected TLR4/
macrophages were similar to those of WT cells (Figure 5A),
and in macrophages lacking both TLR4 and RP105 cytokine
levels were reduced to those measured in RP105/ cells.
Thus, Mtb induced TNF and IL-12p40 production independently
of TLR4, and the interaction of RP105with TLR4 (Divanovic et al.,
2005) did not appear to affect Mtb-induced cytokine responses
of macrophages.
To further investigate the cooperation of RP105 and TLR2,
WT and RP105/ BMM were preincubated with an inhibitory
anti-TLR2 antibody (Meng et al., 2004) and infected with Mtb.
The Mtb-induced TNF release was significantly inhibited by the
anti-TLR2 antibody in both WT and RP105/ macrophages
(WT 65% inhibition, P = 0.024; RP105/ 62% inhibition, P =
0.035), compared to BMM without antibody (Figure 5B). The
IL-12p40 response was inhibited by 57% in WT cells (P =
0.029) in the presence of the anti-TLR2 antibody. In RP105/
BMM, the anti-TLR2 antibody inhibited IL-12p40 release some-
what, but this was statistically significant in only two out of six
experiments (Figure 5B). Thus, in the absence of RP105, cyto-
kine release in response to Mtb required, at least in part, TLR2.
These data support that Mtb-induced RP105-dependent
responses are triggered via TLR2 but that Mtb also stimulates
TLR2-dependent responses that are RP105 independent.
A blocking antibody against murine RP105 is not available.
However, an inhibitory antibody against MD-1 had previously
been used to demonstrate a requirement for MD-1 in RP105-
mediated modulation of LPS-driven B cell activation (Nagai
et al., 2002). To investigate if MD-1 was required for the Mtb-
induced cytokine release in macrophages, WT BMM were
exposed to Mtb in the presence of the inhibitory anti-MD-1 or
an isotype control antibody. Mtb-induced IL-12p40 and TNF
release of WT BMM was inhibited by 60% (P = 0.028) and 53%
(P = 0.012) in cultures treated with the anti-MD-1 antibody
(Figure 5C). In contrast, in parallel cultures of Mtb-infected
RP105/ macrophages, release of IL-12p40 and TNF was not
impaired by the anti-MD-1 antibody (Figure 5C). Expression of
MD-1 on RP105/ BMM was reduced, but not abolished,
compared to that on WT BMM (Figure S1B). Because inhibition
of residual MD-1 did not affect IL-12p40 and TNF release by
RP105/ BMM, we conclude that MD-1 contributes to the
Mtb-induced cytokine response only in the presence of RP105.
TLR2/ BMM expressed RP105 and MD-1 at levels similar
to those in WT BMM (Figure S1B). The inhibitory anti-MD-1 anti-
body did not significantly reduce the Mtb-induced TNF and
IL-12p40 release by TLR2/ BMM (Figure 5D), indicating that(C) Fluorescence profiles for TLR2 (green) andRP105 or CD14 (red) specific staining acquired along the periphery of the cell (approximately 35 mm) as indicated by
the thin white line (arrowheads mark start and end point in enlargement in B).
(D) RP105/ and TLR2/ BMM were stained for RP105 or TLR2 as described for WT cells (A) and subject to confocal microscopy.
(E and F) Immunoprecipitation (IP) and immunoblot (IB) of lysates of (E) Ba/F3 cells stably transfected with RP105/MD-1 or RP105/MD-1 and TLR2 together
and (F) RAW264.7 macrophages. CoIP demonstrating association of RP105 and TLR2 was assessed by IB using anti-RP105 and anti-TLR2 antibodies. An iso-
type-matched rat IgG2a antibody and Ba/F3 cells transfected with RP105/MD-1 but not TLR2 were used as controls. One representative of three independent
experiments is shown.l Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc. 41
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(A) WT, RP105/, TLR2/, TLR4/, RP105/TLR2/, and RP105/TLR4/ BMM were infected with Mtb (MOI 3). Cytokine concentrations in culture superna-
tants were determined 24 hr post infection. Data aremeans ± SD from two independent experiments each performed in triplicates. Raw data of independent wells
of knockout cells were compared to WT cells by unpaired t test. ***P < 0.0001.
(B) WT and RP105/ BMM were preincubated with an anti-TLR2 antibody (1–2 mg/ml) or isotype-matched control antibody (IgG1) for 1 hr and infected with
Mtb (MOI 3). Cytokine release was measured after 24 hr (TNF) and 48 hr (IL-12p40). Four (TNF) and six (IL-12p40) independent experiments performed in trip-
licates were compared by normalizing to control conditions inWTmacrophages (no antibody added), means ± SE are shown. Raw data were compared by paired
t test. *P < 0.05.
(C) Concentrations of IL-12p40 and TNF in culture supernatants of WT and RP105/ BMM that were infected with Mtb (MOI 3) after preincubation (1 hr) with an
inhibitory anti-MD-1 antibody (1–2 mg/ml) or isotype-matched control antibody (IgG2b). Four (TNF) and six (IL-12p40) independent experiments, each performed
in triplicates, were compared by normalizing to control conditions in WT BMM (no antibody added); means ± SE are shown. Raw data were compared by paired t
test. *P < 0.05.
(D) Concentrations of IL-12p40 and TNF in supernatants of WT and TLR2/ BMM, preincubated (1 hr) with an anti-MD-1 or matched isotype control (IgG2b)
antibody, after infection with Mtb (MOI 3). Raw data of three independent wells were compared to control conditions (medium) by unpaired t test. Data points
are means ± SD of triplicate wells of one experiment representative of three. **P = 0.0088, ***P = 0.0005. Cytokine levels in unstimulated macrophage cultures
were below the detection limit and were not significantly influenced in the presence of antibody (data not shown).RP105/MD-1onlycontributed toMtb-inducedcytokine responses
if TLR2 was also expressed. Altogether, these data suggest that
the RP105/MD-1 complex cooperates with TLR2 to activate
macrophages in response to Mtb infection and is required for
a maximal cellular response.
DISCUSSION
Mycobacteria and their subcellular components stimulate TLR
signaling in host cells leading to transcriptional activation,
release of inflammatory mediators, and antimicrobial responses
(Bafica et al., 2005; ; Means et al., 2001; Reiling et al., 2002; Shi
et al., 2005; Thoma-Uszynski et al., 2001; Underhill et al., 1999).
In this study we demonstrated that RP105 was required for
optimal Mtb-induced cytokine release in vitro and in vivo. In
contrast to its role as inhibitor of LPS-induced macrophage
and DC activation, RP105 participates in signaling that lead to
transcriptional activation of some inflammatory genes—e.g.,42 Cell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier IIL-12p40, and posttranscriptional regulation of others, such as
TNF, IL-10, or RANTES, in macrophages stimulated with Mtb.
RP105 lacks the intracellular TIR domain that is required for
TLR-signal transduction via adapters such as MyD88. There-
fore, RP105 is thought to associate with a coreceptor, which
can transduce a signal into the cell (Kimoto et al., 2003). We
provide three lines of evidence that the RP105/MD-1 complex
cooperates with TLR2 to enhance recognition of Mtb and
subsequent immune cell activation: first, RP105 redistributed
with crosslinked TLR2 in the plasma membrane of macro-
phages and both receptors coimmunoprecipitated in two
different cell types. The receptor complex was observed in unin-
fected macrophages indicating a constitutive interaction of
RP105/MD-1 and TLR2. Similarly, TLR2/TLR1- and TLR2/
TLR6-heteromers have been described to pre-exist in the cell
membrane, independently of their respective specific agonists
(Triantafilou et al., 2006).
Second, theMtb 19 kDa lipoprotein and tripalmitoylated hexa-
decapeptide, two confirmed TLR2 agonists (Thoma-Uszynskinc.
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RP105 Is a Coreceptor for TLR2et al., 2001) (Figure 3B), stimulated macrophage and B cell acti-
vation in an RP105-dependent manner. In contrast, RP105 was
dispensable for macrophage responses to the tripalmitoylated
TLR2/1 agonist Pam3CSK4 and the TLR2-dependent lipid and
glycolipid preparations of Mtb (Figures 3A and S5) (Nagai et al.,
2005). The palmitoylation patterns of the cysteine residues in
Pam3CSK4 and the synthetic N-terminal peptide of the 19 kDa
lipoprotein are identical. This suggests that the peptide/protein
part of lipoproteins is important for RP105 agonist activity. Simi-
larly, the amino acid sequence of lipoproteins can contribute to
the specificity of recognition by TLR2/TLR1 and TLR2/TLR6 het-
eromers (Buwitt-Beckmann et al., 2005). The challenge at hand
will be todeterminewhichpeptide feature confersRP105-agonist
properties to Mtb lipoproteins. Furthermore, it remains to be
elucidated if such agonists bind directly to RP105/MD-1 or if
RP105/MD-1 regulates their recognition by TLR2 and potentially
other receptors. Perhaps RP105 provides a level of specificity to
innate immune recognition of microbial lipoproteins by TLR2.
Third, for optimal production of IL-12p40 and TNF in response
to Mtb, both RP105/MD-1 and TLR2 had to be present on
macrophages, and RP105/MD-1 required TLR2 to enhance
Mtb-induced cytokine responses. TNF and IL-12p40 levels
released from Mtb-infected TLR2/ and RP105/TLR2/
macrophages were lower than those from RP105/ cells and
the RP105-independent TNF response to Mtb was partially
TLR2 dependent. Thus, not all Mtb-induced TLR2-dependent
responses require RP105. TLR9 in synergy with TLR2 mediated
IL-12p40 production by Mtb-stimulated macrophages, and both
receptors collaborated in conferring resistance to Mtb (Bafica
et al., 2005). Also, TLR9-dependent activation of RP105/
DCs and B cells by oligonucleotides (CpG) was unimpaired (Di-
vanovic et al., 2005; Nagai et al., 2005). Therefore, the residual
IL-12p40 production of Mtb-stimulated RP105/ and TLR2/
macrophages observed in our studies might have resulted
from TLR9 driven signals.
Taken together, our data suggest that RP105/MD-1 forms
a heteromeric complex with TLR2. Similar to the accessory
proteins CD36 and CD14, which enhance TLR2 signaling in
response todiacylglyceridesand triacylated lipopeptides respec-
tively (Hoebe et al., 2005; Nakata et al., 2006), the RP105/MD-1
complex augments cellular responses to Mtb and mycobacterial
lipoproteins.
Knowledge about the role of RP105 in mediating host immune
responses is limited. RP105/ mice have been reported to
exhibit impaired antibody production in response to LPS,
heat-killed Escherichia coli, and synthetic di- and triacylated lip-
opeptides (Nagai et al., 2005). LPS-challenged RP105/ mice
have alsobeen shown to exhibit elevated TNF levels in the serum,
along with accelerated and amplified signs of endotoxicity (Diva-
novic et al., 2005). Dermal infection of RP105/mice with Leish-
maniamajor led to attenuated disease, withmore rapid control of
the parasite burden (Divanovic et al., 2007). Here, we have
provided evidence that, during infection with live, virulent Mtb,
RP105 is required to optimally induce early systemic cytokine
responses, such as IL-12p40 production, and contributes to
control of bacterial replication and lung pathology.
Although moderate, the increased susceptibility of RP105/
mice to Mtb infection is unexpected. Others and we have shown
that TLR2/mice controlled mycobacterial replication similar toCeWT mice after infection with a low dose of Mtb (Bafica et al.,
2005; Holscher et al., 2008; Reiling et al., 2002; Shi et al.,
2005). However, in one case increased pathology in lungs of
TLR2/ mice was observed (Bafica et al., 2005), and another
study described elevated bacterial loads in TLR2/ mice
5 months post infection (Drennan et al., 2004). Besides its proin-
flammatory functions, prolonged TLR2 signaling induced byMtb
and mycobacterial structures has been shown to inhibit MHCII
expression, antigen processing, and IFNg responsiveness in
macrophages (Fortune et al., 2004; Gehring et al., 2003; Noss
et al., 2001; Pai et al., 2004). Although the net contributions of
these divergent TLR2 functions in vivo remain to be determined,
such lack of inhibition of T cell-activation and -effector mecha-
nisms in TLR2/ mice might lead to control of Mtb infection.
Further studies are required to determine if, perhaps, RP105
contributes to some (e.g., inflammatory cytokine induction) but
not all (e.g., inhibition of antigen presentation and IFNg respon-
siveness) TLR2-dependent signaling events, which could
account for the increased susceptibility of RP105/ mice to
Mtb infection. The agonist specificity of the RP105 contribution
to macrophage activation by TLR2 agonists suggests a selective
involvement of RP105 in TLR2-dependent events. In addition, it
appears that RP105 affects noncanonical TLR signaling,
because the diminished TNF release in response to the TLR2
agonists 19 kDa lipoprotein and synthetic decahexapeptide
was accompanied by indistinguishable patterns of phosphoryla-
tion of MAP kinases and IkB-a in RP105/ and WT macro-
phages. Thus, RP105 might be involved in inducing alternative
regulatory mechanisms of TNF production, such as activation
of Bmx (bone-marrow tyrosine kinase in chromosome X) (Palmer
et al., 2008), TACE (TNF-a converting enzyme) (Black et al., 1997;
Moss et al., 1997), or HMGB1 (high-mobility group box protein 1)
signaling (Andersson et al., 2000). In addition, we speculate that
in a complex in vivo setting RP105might modulate not only TLR2
signaling but may also participate in TLR2-independent immune
responses during infection with Mtb, potentially by enhancing
signaling of other receptors. Further insight into additional func-
tions of RP105 might help understand some of the differences
observed in RP105/ and TLR2/ mice.
In conclusion, RP105 is important for mediating Mtb-induced
cellular immune responses by facilitating recognition of myco-
bacterial lipoproteins. The identification of RP105 as an acces-
sory molecule for TLR2 and potentially other signaling receptors
implies an unexpected role for the RP105/MD-1 complex in
innate immune recognition that goes beyond LPS recognition.
EXPERIMENTAL PROCEDURES
Bacteria, Antibodies, Reagents
Mtb H37Rv was from R. North (Trudeau Institute). The lspA (Rv1539) knockout
was previously reported (Banaiee et al., 2006). To control for polar effects of the
lspAdeletion, thenullmutantwascomplementedwith lspAand the twoflanking
genes, ansA and Rv1540, on an integrative plasmid yielding strain DlspA::lspA
(DlspA comp.). In one construct, a GC deletion was introduced into lspA, at
base pair 386, to cause premature termination of LspA at codon 132 yielding
strainDlspA::lspAmut (DlspA). Complemented cloneswere confirmed by immu-
noblotting for processing of MPT83 lipoprotein (Banaiee et al., 2006).
Mtb lacking the 19 kDa lipoprotein gene (Rv3763) and the complemented
mutant were kindly provided by S.M. Newton and R.J. Wilkinson (Stewart
et al., 2005). Synthetic triacylated lipopeptide (Pam3CSK4), synthetic tripalmi-
toylated hexadecapeptide, containing the N-terminal amino acids of thell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Inc. 43
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RP105 Is a Coreceptor for TLR219 kDa lipoprotein, and peptidoglycan were from EMCMicrocollections; puri-
fied 19 kDa lipoprotein from H37Rv, mycolyl-arabino-galactan-peptidoglycan
(mAGP), total lipid extract, and phosphatidylinositol mannosides (PIM1/2)
were obtained from Colorado State University via the TB Vaccine Testing
and Research Materials Contract; LPS (Salmonella enterica, serovar friedenau
H909) was a gift from H. Brade, Research Center Borstel, Germany; inhibitory
anti-mouse TLR2 (T2.5), mouse IgG1, anti-mouse RP105 (RP/14), inhibitory
anti-mouse MD-1 (MD113), anti-mouse CD14 (Sa2-8), anti-mouse MHCII
(M5/114.15.2), rat IgG2b, and rat IgG2a were from eBioscience.
Mice
RP105/ mice have been described previously (Ogata et al., 2000). TLR2/
mice were from S. Akira (Takeuchi et al., 1999). RP105/TLR2/ and RP105/
TLR4/ mice were obtained by crossing RP105/ mice with TLR2/ or
TLR4/ mice. Double deficiency was confirmed by PCR. Bone marrow
from double KO mice was kindly provided by C.L. Karp and S. Divanovic.
C57BL/6 WT mice were from Jackson Laboratory.
Cellular Responses of Primary Mouse Macrophages
Bone marrow cells from 10-week-old mice were differentiated into macro-
phages for 7 days in DMEM with 20% L cell medium, 10% FBS, 2 mM
L-glutamine, 1 mM Na-pyruvate, and 10 mM HEPES. BMM were infected as
described (Ehrt et al., 2001) or were stimulated with bacterial components
as indicated. Lipid components of Mtb were layered onto cell culture plates
using isopropanol (Rao et al., 2005). After complete evaporation of the solvent
macrophages were seeded into coated wells.
For inhibition of cytokine release, BMM were incubated for 1 hr with anti-
bodies as indicated before stimulation. Cytokine and chemokine concentra-
tions in supernatants were determined by ELISA (IL-12p40, BD OptEIA; R&D
Duo Set, all others). For PCR total RNA was isolated post stimulation and
reverse transcribed using oligo-dT nucleotides. For quantitative TaqMan
PCR (ABIPrism 7900HT, Perkin Elmer; LightCycler 480, Roche) sequences
of gene-specific primer pairs and probes were as described (Shi et al., 2003,
2005); sequences for GAPDH, IL-12p40, MD-1 and RP105 primers and probes
are available upon request. Gene expression was normalized to expression of
GAPDH (2(crossing point GAPDH-crossing point gene)).
For immunoblots, cell lysateswere separatedbySDS-PAGEandblottedonto
nitrocellulosemembrane.Proteindetectionwasperformedusinganti-p38, anti-
phospho-p38, anti-phospho-JNK, and anti-phospho-IkB-a antibodies (Cell
Signal Technologies); a secondary IRDye-800-conjugated donkey anti-rabbit
antibody; and the Odyssey Infrared Imaging System (LI-COR Biosciences).
Expression of Surface Markers
BMM were left untreated or stimulated with Mtb (multiplicity of infection [MOI]
1 or 10) for 18 hr. Cells were stained with phycoerythrin (PE) -conjugated
specific anti-RP105 or anti-MD-1 antibodies or an Alexa647-coupled anti-
TLR2 antibody. Matched isotype antibodies were used as controls. Splenic
B cells were prepared by CD43-negative sorting (AutoMACS) and stimulated
as indicated for 24 hr. Cells were stained with biotinylated anti-CD86 (GL-1)
and biotinylated anti-CD69 (H1.2F3) antibody (eBioscience), followed by
PE-conjugated streptavidin (Southern Biotech). Data were analyzed using
WinMDI 2.8 and FlowJo Softwares.
Microscopy
BMM were seeded into 1.5 mm glass bottom dishes (gift of Dr. Tim McGraw,
Weill Cornell Medical College) and left untreated or stimulated with heat-killed
Mtb for 2 hr at 37C. Cells were fixed and permeabilized with 3.3%paraformal-
dehyde (PFA) + saponin, blocked with 5% FBS, incubated with anti-mouse
RP105 or rat IgG2a and subsequently incubated with Alexa546-conjugated
goat anti-rat antibody (Molecular Probes).
To stain TLR2 and RP105, cells were treated with 10% mouse serum and
incubated at 4C with anti-TLR2 or matched IgG1 antibody. Each was prela-
beled with Alexa488-conjugated Fab fragments (Zenon, Molecular Probes).
Cells were washed, fixed with 3.3% PFA, and stained for RP105 expression
as described above. For patching experiments, macrophages were washed,
blocked with 10% mouse serum and incubated at 4C with anti-TLR2 or
IgG1antibodyprelabeledwith Alexa488-conjugated Fab fragments.Crosslink-44 Cell Host & Microbe 5, 35–46, January 22, 2009 ª2009 Elsevier Ining was achieved by incubation with a goat-anti-mouse IgG F(ab0)2 for 3 hr on
ice. After PFA fixation, cells were counterstained for RP105, CD14, or MHCII.
A Zeiss LSM510 laser-scanning confocal microscope (633/1.4 numerical
aperture oil objective) was used for image acquisition. Fluorescence images
of all sampleswith similar stainingswithin one experiment were acquired under
identical conditions, and images are displayed at the same contrast so that
they are directly comparable. Images were processed using LSM510 software
(low pass filter, funnel 3 3 3; identical parameters for brightness and contrast
for samples stained with the same antibody). Line scans of approximately
35 mm along peripheries of cells were obtained using the ‘‘profile’’ function.
Immunoprecipitation (IP)
Antibodies against mouse RP105 (RP/14), mouse TLR2 (CB225; Wistar rats
immunized with RAW264.7 cells emulsified in zymosan, specificity for TLR2
confirmed via FACS using WT, TLR2/, TLR1/, TLR6/, and RP105/
BMM [T.K. and M.K., unpublished data]), or isotype-matched rat IgG2a were
immobilized on NHS-activated Sepharose beads (GE Healthcare Sciences)
and used for IP. Precipitates were separated by SDS-PAGE and blotted
onto PVDF membrane (Millipore) and immunobloted using a polyclonal rabbit
anti-mouse RP105 antibody (rabbits immunized with oligopeptide corre-
sponding to aa 651–661 of mRP105 [KYFLRWKYQHI]; specificity confirmed
by Immunoblot) and a rat anti-mouse TLR2 antibody (1–10; IgG2a; Wistar
rats immunized with GST-tagged cytoplasmic portion of mTLR2; specificity
confirmed by Immunoblot) followed by alkaline phosphatase-coupled
secondary goat antibodies (AmericanQualex); NBT and BCIP solutions (Prom-
ega) were used for development.
Mouse Infections
Ten-week-old mice were infected with Mtb using an aerosol chamber
(Glas-Col, Inc.) by nebulizing 5 ml bacterial single cell suspension in PBS
at23 108 bacilli/ml (low dose; inoculum sizes 175 ± 98 CFU per lung, deter-
mined by plating lung homogenates 24 hr post infection) or23 109 bacilli/ml
(high dose; inoculum sizes 5600 ± 2600 CFU per lung). Lungs were homoge-
nized in PBS and plated for CFU at indicated times. The upper left lobe was
fixed in 10% formalin and lung sections were stained with hematoxylin and
eosin (H&E). IL-12p40 concentrations in serum were determined by ELISA
(Beckton Dickinson). All animal studies were approved by the Institutional
Animal Care and Use Committee, Weill Cornell Medical College.
Statistical Analyses
Raw data of experimental groups were analyzed by two-tailed t test. mRNA
levels and cytokine concentrations are represented as mean ± standard devi-
ation (SD) of triplicates. For depiction of results of multiple experiments, data
are represented as means of values of individual experiments ± standard error
(SE). To measure the inhibitory effect of antibodies in multiple experiments,
cytokine concentrations under different culture conditions were normalized
to control conditions and represented as means ± SE.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found online at http://www.
cell.com/cellhostandmicrobe/supplemental/S1931-3128(08)00400-9.
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